8-K: NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results, Issues Optimistic 2025 Revenue Guidance

NEXGEL announces record fourth quarter and full year 2024 financial results, with revenue growth exceeding 100% for the third consecutive year, and issues revenue guidance of $13 million for 2025 with expected positive EBITDA.

Summary

• NEXGEL reported record fourth quarter and full year 2024 financial results.
• Fourth quarter revenue reached $3.04 million, a 181% increase compared to $1.08 million in the same period last year.
• Full year 2024 revenue totaled $8.69 million, up 112% from $4.09 million in 2023.
• The company achieved over 100% full year and fourth quarter revenue growth year-over-year for the third consecutive year.
• NEXGEL is issuing revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year.
• Gross profit for the fourth quarter was $1.13 million, with a gross profit margin of 37.2%.
• The net loss for Q4 2024 was $0.85 million, including a non-recurring one-time inventory write off of $0.24 million.
• The company's EBITDA for Q4 2024 was ($0.73) million, and adjusted EBITDA was ($0.62) million.
• Full year gross profit was $2.75 million, with a gross profit margin of 31.6%.
• The net loss for the full year 2024 was $3.28 million.
• EBITDA for the full year was ($2.76) million, and adjusted EBITDA loss was ($2.43) million.
• As of December 31, 2024, NEXGEL had a cash balance of $1.81 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenue growth and expectations for future profitability. While there are net losses reported, the company is showing strong growth and strategic partnerships, indicating a positive trajectory.

Positives

• Significant revenue growth in both Q4 and full year 2024.
• Improved gross profit margins compared to the previous year.
• Successful acquisition and growth of the Silly George brand.
• New supply agreement with Cintas for SilverSeal.
• Partnership with STADA to launch Histasolv in North America.
• Guidance for $13 million in revenue and positive EBITDA in 2025.
• Narrowing EBITDA loss compared to the previous year.

Negatives

• Net loss reported for both Q4 and full year 2024.
• EBITDA remains negative, although the company expects to achieve positive EBITDA in 2025.
• One-time inventory write-offs impacted Q4 2024 results.

Risks

• The company's ability to achieve its revenue guidance of $13 million for 2025 and positive EBITDA is subject to various market and operational risks.
• The company's first quarter is seasonally the weakest, with revenue expected to be at least $2.75 million.
• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.

Future Outlook

NEXGEL expects revenue to be at least $2.75 million in the first quarter of 2025 and to generate at least $13 million in revenue for the full year 2025, with the expectation of achieving positive EBITDA during the year.

Management Comments

• Adam Levy, NEXGEL's Chief Executive Officer, commented that the fourth quarter and full year 2024 were record periods for NEXGEL across all key financial measures.
• Mr. Levy stated that the company successfully grew full year and fourth quarter revenue over 100% year-over-year for the third consecutive year.
• Mr. Levy noted that the company's EBITDA loss continued to narrow when compared to Q4 2023.
• Mr. Levy mentioned that the company made its first shipments of SilverSeal to Cintas during the fourth quarter of 2024, which continues into the first quarter of 2025.
• Mr. Levy stated that the company expects to generate at least $13 million in revenue for 2025 and achieve positive EBITDA during the year.

Industry Context

NEXGEL's focus on high-water-content hydrogel products positions it in a growing market for healthcare and consumer applications. The partnership with STADA and supply agreement with Cintas indicate a strategic approach to expanding market reach and product offerings. The company's growth aligns with the increasing demand for advanced materials in the healthcare and beauty industries.

Comparison to Industry Standards

• Comparing NEXGEL to competitors in the advanced wound care and hydrogel market is difficult without specific competitor data in this report.
• Companies like Smith & Nephew, 3M, and Convatec are established players in the broader wound care market, but their specific hydrogel product performance would need to be analyzed for a direct comparison.
• NEXGEL's revenue growth of over 100% year-over-year for three consecutive years suggests strong performance relative to industry averages, but a detailed benchmark analysis would require more granular market data.
• The company's focus on branded consumer products and contract manufacturing diversifies its revenue streams, which could provide a competitive advantage compared to companies solely focused on one area.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and improved financial outlook.
• Employees: Potential for job security and growth opportunities due to company expansion.
• Customers: Continued access to innovative hydrogel products.
• Suppliers: Increased business opportunities due to higher production volume.
• Creditors: Improved creditworthiness due to revenue growth and positive EBITDA expectations.

Next Steps

• Continue to execute on growth strategy in branded consumer products and contract manufacturing.
• Focus on achieving revenue guidance of $13 million for 2025 and positive EBITDA.
• Monitor the results of the institutional review board study with Innovative Optics US.
• Expand partnerships and supply agreements to further increase revenue streams.

Key Dates

Keywords

NEXGEL, financial results, revenue, hydrogel, EBITDA, gross profit, net loss, guidance, consumer products, contract manufacturing